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PERSPECTIVES IN BASIC SCIENCE
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Role of macromolecular IgA in IgA nephropathy. Primary IgA
nephropathy (IgAN) is the most common form of primary
glomerulonephritis, leading to progressive renal failure in al-
most one third of the patients. The disease is characterized by
mesangial deposits of IgA. The pathogenesis of IgAN remains
incompletely understood. The basic abnormality of this disorder
lies within the IgA immune system rather than in the kidney. El-
evated levels of IgA and IgA-containing complexes are found in
sera of most patients with IgAN, but increased levels alone are
not sufficient to develop IgAN. Therefore abnormal physico-
chemical properties of circulating IgA, such as size, charge, and
glycosylation may play a role. This is supported by the pres-
ence of altered glycosylation of serum and mesangial IgA in
patients with IgAN. Although the precise origin and nature of
the mesangial IgA deposits are still uncertain, they contain at
least in part macromolecular IgA, which may be derived from
circulating IgA-containing complexes. Recently, novel insights
have been obtained in the molecular composition of circulat-
ing high-molecular-weight IgA, which might include complexes
with underglycosylated IgA1 and IgA-CD89 complexes. In this
review various aspects of macromolecular IgA in relation to
IgAN will be discussed.
Primary IgA nephropathy (IgAN) is the most common
form of primary glomerulonephritis with a variable spec-
trum of clinical presentations, leading to progressive renal
failure in almost one third of the patients [1, 2]. The dis-
ease is characterized by mesangial deposits of IgA and
C3, although IgG and less frequently IgM may also be
codeposited. The mesangial IgA is of the IgA1 isotype
although in a few cases codeposition of IgA2 has been
observed.
IgAN is typically diagnosed in young adults, males
more commonly affected than females. About 40% of
cases have recurrent episodes of macroscopic hematuria,
frequently preceded 1 or 2 days earlier by infections.
In the majority of patients, the disease has an indolent
course manifested by persistent or intermittent micro-
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scopic hematuria. Rapidly progressive renal failure is an
uncommon event, but acute renal failure (ARF) can de-
velop in individual cases either on the basis of crescentic
glomerulonephritis or on the basis of renal tubular ob-
struction by red blood cells [3]. On follow-up mild pro-
teinuria usually develops which may progress to heavy
proteinuria in the nephrotic range. Proteinuria frequently
precedes the development of hypertension [4, 5]. The
level of proteinuria, the severity of hypertension, and the
degree of microscopic hematuria are indicators of pro-
gression of the disease, manifested by progressive loss of
glomerular filtration rate (GFR) [6].
The pathogenesis of this disease remains incompletely
understood. Reports of recurrent IgA deposits in normal
kidneys transplanted in recipients with IgAN provide ev-
idence that the basic abnormality in this condition lies
within the IgA immune system rather than in the kid-
ney [7]. This is further strengthened by the observation
that the IgA deposits disappear when a graft contain-
ing mesangial IgA deposits is accidentally transplanted
in recipients not suffering from IgAN [8]. The clinical
association between exacerbations of the disease and
mucosal infections has promoted the view that IgAN is
connected with the mucosal immune response. Further,
physicochemical properties, like abnormal glycosylation
of serum IgA1 are thought to play an important role in
the pathogenesis of mesangial IgA deposition.
Although the origin and nature of the IgA deposits
remains uncertain, the mesangial IgA has been found to
consist at least in part of macromolecular IgA [9, 10].
In this review several aspects of macromolecular IgA in
relation to IgAN will be discussed.
IMMUNOGLOBULIN A
The human IgA immune system consists of two com-
partments: the mucosa-associated lymphoepithelial tis-
sue (MALT) and the bone marrow-plasma compartment
[11, 12]. The IgA molecule is a tetramer, consisting of
two identical light (j or k) and two heavy (a) chains.
It occurs in two isotypic forms, IgA1 and IgA2. IgA
is produced in higher quantities than all other isotypes
combined, with the mucosal immune system as the main
production site. In contrast to other immunoglobulins,
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Fig. 1. Schematic representation of different forms of immunoglobu-
lin A (IgA) in the circulation. Serum IgA consists of monomeric IgA
(mIgA),dimeric IgA (dIgA), which includes two mIgA joined by J
chain) and polymeric IgA (pIgA). Although mIgA and IgA have a well-
defined molecular composition, pIgA may be present as mIgA and/or
dIgA containing aggregates or immune complexes or IgA associated
with other proteins.
human IgA displays unique heterogeneity in its molecu-
lar forms, each with a characteristic distribution in various
body fluids. Circulating IgA is almost all produced in the
bone marrow and contains approximately 90% IgA1 and
10% IgA2. Its j/k light chain ratio varies between 1.3
and 1.55 in different studies [13, 14]. It exists predomi-
nantly in the monomeric form with a small proportion
as macromolecular IgA, which consists of dimeric IgA
(dIgA) and polymeric IgA (pIgA). dIgA consists of two
monomeric IgA units joined by the bridging protein J
chain. The precise composition of pIgA is still unknown.
These IgA-containing complexes might be aggregates of
IgA, IgA containing immune complexes or complexes
of IgA associated with other proteins (see Fig. 1). The
IgA found in secretions, termed secretory IgA (sIgA), is
predominantly dimeric in form. At mucosal sites dIgA is
specifically bound by the pIg receptor (pIgR) on the baso-
lateral surfaces of the mucosal epithelium, transcytosed
through the epithelial layer, and released into mucosal
secretions as covalent complex of dIgA and the cleaved
pIgR ectodomain (secretory component).
Serum IgA in IgAN
Levels of plasma IgA1 are elevated in about half of the
patients with IgAN [15–17], which appears to be the re-
sult of an increased production of this isotype by the bone
marrow [18–21] and by a low elimination rate of the liver.
This increase is restricted to the IgA1 subclass [17] with a
predominance of k light chains [13, 14]. Further increased
circulating IgA-containing complexes are present in pa-
tients with IgAN. The elevated plasma levels of IgA1
and/or IgA1-containing immune complexes alone are not
sufficient to cause mesangial deposition of IgA1. This
is witnessed by the rare occurrence of IgAN in patients
with IgA1 myeloma or infection with the human immun-
odeficiency virus (HIV) type I, which diseases are also
characterized by high circulating IgA1 or IgA-containing
complexes [22]. Although in children with IgAN circu-
lating macromolecular IgA levels correlate with bouts of
macroscopic hematuria [23, 24], in adults the correlation
with disease activity is less clear [25].
O-glycosylation of IgA
The majority of serum proteins are glycoproteins. Sug-
ars are attached to proteins as N-linked sugars (con-
nected to asparagine residues) or O-linked sugars (con-
nected to serine and threonine residues). The human
IgA1 molecule is one of the few serum glycoproteins
which possesses O-linked oligosaccharide (O-glycan)
side chains in its hinge region [26, 27] (see Fig. 2). There
are nine potential O-glycosylation sites (five Ser and
four Thr) in each IgA1 hinge peptide, causing a vari-
able number of O-glycan side chains [28]. The funda-
mental structure of the O-glycans is the linkage between
the a-anomeric carbon atom in N-acetylgalactosamine
(GalNAc) and the hydroxy group of serine or threonine
[GalNAc-O-Ser (Thr)]. The GalNAc residue in the gly-
cans of the human IgA1 hinge may be extended with b1,3-
linked galactose (Galb1,3GalNAc). Further, sialic acid
[(N-acetylneuraminic acid (NANA)] could bind to galac-
tose through an a2,3 link and to N-acetyl galactosamine
(GalNAc) through an a2,6 link. Therefore, there could
be several varieties of O-glycans structures in the hinge
region of IgA1. In one study it was found that O-glycans
were located at Thr228, Ser230, and Ser232, while O-
glycan sites at Thr225 and Thr236 were partially occupied
in the hinge peptide [27].
Several studies have shown that there is a defect in
galactosylation of serum IgA1 from patients with IgAN
[29–32]. An increased binding of GalNAc-specific lectins
to serum IgA1 in IgAN was found, suggesting the un-
dergalactosylation of the IgA1 hinge glycopeptides. This
abnormal O-glycosylation has been confirmed by more
precise analytic methods, including fluorophore-assisted
carbohydrate electrophoresis [33] and matrix-assisted
laser desorption/ionization time-of-flight mass spectrom-
etry [34]. Further, Gal-deficient IgA1 was only found
in the circulation of Henoch-Scho¨nlein purpura patients
in the presence of a clinical nephritis [35]. The under-
lying defect resulting in reduced galactosylation of the
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Fig. 2. Structure of immunoglobulin A
(IgA1) and the amino acid sequence in
the hinge region and possible O-glycan
structures. Each IgA1 hinge region possesses
nine O-linked oligosaccharide (O-glycan)
side chains (five serine and four threonine).
The hydroxy group of serine or threonine is
linked to the a-anomeric carbon atom in N-
acetylgalactosamine (GalNAc). The GalNAc
residue may be extended with b1,3-linked
galactose (Gal). Further, N-acetylneuraminic
acid (NANA) (sialic acid) could bind to Gal
through an a2,3 link and to GalNAc through
an a2,6 link.
O-linked glycans of the IgA1 hinge region is still un-
known. Galactosylation of O-linked glycans is performed
by the intracellular enzyme b1,3 galactosyltransferase. A
reduced expression or function of this enzyme may be
involved [31]. In a single study a reduced activity of this
enzyme was found in circulating B cells in patients with
IgAN [36]. Further, in a mouse model an altered balance
between Th1 and Th2 lymphocytes has been proposed as
explanation for abnormal glycosylation of IgA [37].
Altered O-glycosylation might favor self-aggregation
of IgA1 [38] and formation of circulating IgA-containing
immune complexes [39]. There is also evidence for in-
creased binding of abnormally O-glycosylated IgA1 to
extracellular matrix (ECM) components [38, 40]. These
aspects will be discussed later.
CIRCULATING IMMUNE COMPLEXES
The glomeruli in IgAN are characterized by diffuse and
generalized mesangial deposition of IgA, usually accom-
panied by deposition of the C3 component of comple-
ment, and variable codeposition of IgG, IgM, or both.
These IgA deposits may be derived from circulating im-
mune complexes, suggesting an immune complex patho-
genesis for the mesangial IgA deposits. IgA-immune
complex levels may increase after food ingestion both in
patients with IgAN and healthy controls. Although most
studies are not controlled for food intake, elevated levels
of IgA1 and IgA1 containing circulating immune com-
plexes are elevated in sera of most IgAN patients [41–
43]. Various techniques, like the conglutin test [41], solid-
phase enzyme-linked immunosorbent assays (ELISAs)
[43], and binding tests to solid-phase anti-C3 [42] have
been used. However, these assays do not distinguish be-
tween true antigen antibody complexes and other forms
of macromolecular IgA.
To obtain conclusive evidence for an immune complex
pathogenesis, it should be demonstrated that the same
antigen and/or antibody present in circulating immune
complex is present in glomeruli. An association between
the classes of immunoglobulins in circulating immune
complexes and those in glomerular deposits in patients
with IgAN has been reported [44]. Further IgA1 is pre-
dominantly present in both IgA-containing circulating
immune complexes [41, 42] and in mesangial deposits
[45] in patients with IgAN. Additional results suggesting
that immune deposits originate from circulating immune
complexes includes the presence of Gal-deficient IgA1
in both circulating immune complexes [32, 39, 46] and
mesangial deposits of patients with IgAN [47, 48].
IgA1-IgA1 and IgA-IgG immune complexes
Removal of carbohydrates from the IgA1 molecule re-
sults in noncovalent self-aggregation [38]. Therefore un-
derglycosylation of IgA1 in IgAN may lead directly to
formation of IgA1-IgA1 complexes. Further, incomplete
galactosylation of O-linked glycans in the IgA1 hinge
region may result in the exposure of underlying neoanti-
genic GalNAc [32, 39]. This neoantigen may be recog-
nized by naturally occurring antibodies (IgG or IgA1
specific for GalNAc) and lead to formation of circulat-
ing immune complexes [39]. The presence of antibodies
bound to GalNAc residues in the hinge region reduces the
hepatic clearance of the circulating immune complexes,
which results in higher levels [39]. These circulating im-
mune complexes are found to bind better to mesangial
cells compared to circulating immune complexes from
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healthy controls [46]. IgA rheumatoid factors has been
described in 50% of patients with IgAN, but a correla-
tion between IgA rheumatoid factor and the presence of
IgG in glomerular deposits was not present [49].
IgA fibronectin complexes
Although complexes of IgA with fibronectin are found
to be increased in patients with IgAN, the pathogenic
role or diagnostic value of these increased levels remains
doubtful [50–52]. The specificity of assays to detect IgA
fibronectin complexes has been controversial [51–53] and
high levels of IgA fibronectin aggregates are also found
in patients with Henoch-Scho¨nlein purpura without renal
involvement and patients with cirrhotic liver disease in
the absence of urinary abnormalities [51]. Elevated IgA
fibronectin levels may be only a reflection of raised serum
IgA levels. Recently, a 43 kD carboxy-terminal fragment
of fibronectin was detected only in serum samples of pa-
tients with IgAN [54], but its pathogenic role in IgAN is
still unknown.
Uteroglobin is an anti-inflammatory protein, which
interferes with IgA fibronectin interaction. Recently,
uteroglobin-deficient mice were generated. These mice
showed features of human IgAN with glomerular depo-
sition of IgA, C3, fibronectin, and collagen [55]. Further,
these mice developed hematuria and a nephrotic syn-
drome progressing to renal insufficiency. It was hypothe-
sized that due to the absence of uteroglobin, an excess of
IgA fibronectin complexes were formed and deposited in
the mesangial area. However, in a recent study [56] circu-
lating uteroglobin levels were found not to be reduced in
patients with IgAN, suggesting that another pathogenesis
of mesangial IgA depostition may occur in patients with
IgAN as compared to uteroglobin-deficient mice.
Dietary and microbial antigen containing
immune complexes
In many studies one has searched for antigens that may
be responsible for immune complex formation. Although
serum antibodies to both dietary antigens and various
infectious agents have been identified in patients with
IgAN, no consistent antigen associated with mesangial
IgA deposition was identified.
Other circulating IgA-containing complexes
Recently, it has been suggested that the IgA receptor
FcaRI/CD89 may contribute to formation of pIgA [57]
and play a role in the pathogenesis of IgAN [58]. This
IgA receptor is a type I receptor glycoprotein, expressed
on myeloid cells. Cross-linking of CD89 triggers diverse
processes, including phagocytosis, superoxide generation,
antibody-dependent cellular cytotoxicity, and release of
inflammatory mediators. Further, the FcaRI/CD89 re-
ceptor has been reported to play a crucial role in the
clearance of IgA complexes [59, 60]. Upon activation,
a soluble form of CD89 is released from the surface
of monocytes and monocytic cell lines [61]. These sol-
uble CD89 molecules circulate in a complex covalently
linked with IgA in the high-molecular-mass fractions of
serum IgA [57]. These high-molecular-mass complexes
of CD89 IgA can be distinguished from J chain contain-
ing dIgA and it has been hypothesized that J chain and
CD89 are competing for the same cysteine. In analogy
with the pIgR system, we suggested that the mechanism
of covalently linkage of IgA to CD89 is most likely, that
reshuffling of cysteine bonds takes place in an intracel-
lular compartment [57]. When the covalently linked IgA
CD89 complexes are released, they circulate in the high-
molecular-mass fractions of serum IgA, suggesting that
CD89 might contribute to the formation of serum pIgA
[57]. Two soluble forms of CD89 have been reported in
human serum: a highly glycosylated 50 to 70 kD protein,
which was found to be elevated in polyethylene glycol
(PEG) serum precipitates from patients with IgAN [58]
and a 30 kD protein, which does not seem to be specific
for IgAN [62]. In the first study, soluble CD89 IgA com-
plexes were found only in the circulation of patients with
IgAN and transgenic mice expressing human CD89 on
monocytes/macrophages spontaneously developed a pic-
ture compatible with IgAN [58]. Therefore, a pathogenic
role for IgA CD89 complexes in IgAN has been sug-
gested. However, CD89 was not detectable in renal biop-
sies. Recently, we found that serum levels of IgA CD89
complexes were not increased in patients with IgAN com-
pared to healthy controls [62]. These data strongly sug-
gest that CD89 can circulate in different molecular forms.
Therefore, additional studies are required to further an-
alyze the role of IgA CD89 complexes in IgAN.
IGA IMMUNE RESPONSE
The presence of a clinical association between exacer-
bations of the disease and upper respiratory tract infec-
tions suggests a relation between the mucosal immune
system and the deposition of IgA in the renal mesangium.
Increased numbers of pIgA1-producing cells in both ton-
sils [63] and bone marrow [18, 21, 64] and increased
serum IgA levels suggested a state of hyperresponsive-
ness. However, IgA and IgA subclass concentrations in
mucosal secretions have been found to be similar in pa-
tients with IgAN as compared to healthy subjects [25].
A deficient primary mucosal immune system was found
and it was hypothesized that this deficient primary im-
mune response might lead to recurrent mucosal infec-
tions and persistence of the antigenic stimulus in patients,
whereas healthy individuals succeed in the elimination
or exclusion of the antigen by a more effective mucosal
immune response [25]. The resulting ongoing or repeated
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stimulation of the immune response in IgAN patients may
eventually lead to appropriate protection at the mucosal
level. However, as a consequence an increased number
of antigen-specific B cells are generated, resulting in a
overproduction of IgA1 antibodies in the systemic com-
partment [25]. It has been found that macromolecular
IgA in serum is especially increased in the acute phase
of the immune response [12]. Infection or immunization
(parenteral or mucosal) with nonviable or live vaccines
induces the synthesis of antigen-specific macromolecular
weight IgA in the initial phase of the immune response. In
chronic viral or bacterial infections a shift has been found
to monomeric IgA in the chronic stage of the disease [12].
Therefore, systemic macromolecular IgA levels may re-
flect the phase of the systemic IgA immune response. An
exaggerated systemic IgA response to chronic mucosal
infections was confirmed in another study [65]. Patients
with IgAN with infections caused by Helicobacter pylori
had markedly elevated systemic levels of IgA anti-H. py-
lori, which was predominantly IgA1 and polymeric of na-
ture. Traffic of lymphocytes plays an important role in the
link between the mucosal and systemic IgA system [25].
Further studies are required to examine whether a re-
location of mucosal lymphocytes to systemic sites may
explain the increased systemic IgA response to mucosal
infections [65].
MESANGIAL IGA
Mesangial IgA has been found of the IgA1 isotype [45,
66], although also the presence of IgA2 in renal biopsies
has been reported [67]. Its light-chain composition is pre-
dominantly k IgA [68]. Although increased serum levels
of IgA1 [15–17] and k IgA [13, 14] have been found in pa-
tients with IgAN, their pathogenic role is still unknown.
Secretory component has rarely been identified in renal
biopsies, suggesting a systemic origin of mesangial IgA.
Presence of macromolecular IgA in mesangium
Mesangial IgA has been found to consist at least in part
of macromolecular IgA [9, 10]. Methods used to demon-
strate the polymeric nature of mesangial IgA are anal-
ysis of the capacity to bind free secretory component or
demonstration of the presence of J chain in renal biopsies.
However, both techniques are hampered that not only
dIgA, but also codeposited IgM contains J chain and can
bind noncovalently to free secretory component. Several
groups have performed binding studies to free secretory
component in renal tissue of patients with IgAN, Henoch-
Scho¨nlein purpura, systemic lupus erythematosis (SLE),
and alcoholic liver disease (ALD) [9, 66, 69–71]. In re-
nal biopsies of patients with IgAN, the presence of bind-
ing to secretory component varied from 10% to 100%
[66, 69].
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Fig. 3. Molecular composition of serum immunoglobulin A (IgA).
Size fractionation of human serum shows the presence of monomeric
IgA (mIgA), dimeric IgA (dIgA) and polymeric IgA (pIgA). High-
molecular-weight IgA (HMW-IgA) or macromolecular IgA has been
defined as the dimeric and polymeric IgA fractions together (upper part
of figure). Aggregates of IgA, IgA-containing immune complexes, or
complexes of IgA associated with other proteins may be present in both
dimeric and polymeric fractions (lower part of figure).
Studies demonstrating the presence of J chain have
been hampered by the poor specificity of some anti-J
chain antibodies. J chain was present in most patients
with IgAN [10, 66, 69, 72, 73]. In some of the biopsies
J chain was present in the absence of IgM. It has to be
realized that binding to secretory component and/or the
presence of J chain in renal biopsies does not mean that
immune deposits are predominantly constituted of pIgA.
The results are obtained with qualitative techniques and
suggest only that mesangial IgA consists at least in part
of dIgA. These studies do not provide evidence concern-
ing the presence of pIgA in renal biopsies. However, in
one mentioned study [9] eight eluates were analyzed un-
der nondissociating conditions (pH 6.8) and five eluates
were subjected to chromatography under acidic condi-
tions (pH 3.5). Under neutral and acid conditions, 52%
and 69%, respectively, of the eluted IgA had a molecular
weight ≥320 kD. Eluates that were radioactively labeled
and fractionated by sucrose density gradient ultracen-
trifugation showed a peak in the high-molecular-weight
range in three out of five patients examined [10].
Glycosylation of mesangial IgA
When the charge of eluted IgA, obtained from re-
nal biopsies of five patients, was analyzed by isoelectric
focusing on agarose, the eluated IgA was found to be
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Fig. 4. The three pathways of complement activation. Each complement-activation pathway generates a C3 convertase (C4b2a/C3bBbP), which
mediates cleavage of C3, followed by activation of the terminal complement pathway and formation of the membane attack complex.
predominantly anionic, which might be related to ab-
normal glycosylation [9]. In another study [48], IgA1
was obtained from 290 renal biopsy specimens of pa-
tients with IgAN. Analyzing the pooled IgA by mass
spectrometry, a reduced O-glycosylation of the glomeru-
lar IgA was found. In a third study [47], IgA1 was
eluted from glomeruli from three kidneys, obtained after
nephrectomy or postmortem. Binding of the eluted IgA1
to lectins, specific for terminal GalNAc, was markedly
higher as compared to serum IgA1, suggesting that ab-
normal O-glycosylated IgA1 molecules are more likely
to deposit in the kidney.
MESANGIAL IGA DEPOSITION
The mechanism leading to mesangial IgA deposition is
still unknown. There is no direct evidence to suggest that
the deposited IgA is directed against specific glomeru-
lar antigens. Although IgA may bind to receptors or
ECM proteins, other mechanisms like binding of asso-
ciated proteins in IgA-containing complexes, may also
be an option. Many investigators have studied direct in-
teractions of serum IgA with mesangial cells and matrix
components. Until now, several IgA receptors have been
identified on several cell types: the hepatic asialoglyco-
protein receptor (ASPGR), the myeloid FcaRI/CD89 re-
ceptor, the pIgR on epithelial cells in the mucosa, the
Fca/l receptor on the majority of B lymphocytes and
macrophages, and the recently as IgA receptor described
transferrin receptor [74–78]. In addition, poorly charac-
terized IgA-receptors have been reported on various cell
types [46, 79–82]. Studies from several groups have now
excluded the asialoglycoprotein, the FcaRI/CD89 and
the pIg receptor as mesangial cell IgA receptor [46, 79,
82–84]. Although mesangial cells express mRNA for the
Fca/l receptor [85], IgA1 binding to mesangial cells was
not inhibited by IgM [79], suggesting a less important
role for this receptor concerning mesangial IgA deposi-
tion. Expression of CD71 mRNA (transferrin receptor)
by proliferating mesangial cells was recently confirmed
[46]. CD71 binds pIgA1 and has a higher avidity for un-
derglycosylated IgA1 and IgA1 complexes than normal
IgA1 [76, 86]. Characterization of other IgA receptors
on mesangial cells requires additional attention. The Fc
portion of the IgA1 molecule probably mediates binding
of IgA1 to mesangial cells, because both intact IgA1 and
the Fc portion, but not its Fab fragment inhibits bind-
ing of IgA1 to mesangial cells [46, 79]. Underglycosyla-
tion of IgA may lead to selfaggregation and formation
of IgA1-IgA1 and IgA1-IgG immunecomplexes. Macro-
molecular IgA binds better to mesangial cells as com-
pared to monomeric IgA. It is not quite clear what the
impact is of the abnormal glycosylation of IgA concerning
this increased binding of macromolecular IgA to mesan-
gial cells. Recently, it was found that Gal-deficient pIgA1
myeloma protein bound better to mesangial cells as
compared to unmodified pIgA1 myeloma [46]. However,
circulating immune complexes containing aberrantly gly-
cosylated IgA from patients with IgAN bound even bet-
ter [46], suggesting that not the abnormal glycosylation
alone, but additional factors also play a role in the bind-
ing of pIgA to mesangial cells. Although binding of IgA
to mesangial cells might be mediated by IgA receptors,
some investigators found that the adhesion activity of
serum IgA to ECM proteins, such as type IV collagen,
fibronectin, and laminin was significantly increased in pa-
tients with IgAN [22, 40, 87, 88]. Since removal of carbo-
hydrates from the IgA1 molecule resulted in a significant
increase in adhesion to ECM proteins [38], underglyco-
sylation of the IgA molecule as observed in IgAN may
play a role.
After binding of IgA to mesangial cells a number of
events can be triggered. In vitro studies have demon-
strated an enhanced proliferation [89, 90], increased cy-
tokine release [89–91] and enhanced production of ECM
[92]. In IgAN mesangial IgA deposits may be accompa-
nied by IgG and/or IgM and C3, but the C1q component
of complement is rarely found. It is generally accepted
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that IgA does not activate the classical pathway of com-
plement [93]. Activation of the alternative complement
pathway by IgA is supported by both in vitro and in
vivo observations [94–97]. Recently, it was shown that the
complement system can also be activated by human IgA
via the lectin pathway, which is mainly driven by mannan-
binding lectin (MBL) [93]. In Figure 4 the three pathways
of complement activation are shown. Activation of the
lectin pathway in the renal mesangium is supported by
deposition of MBL and MBL associated serine protease
(MASP-1) in association with IgA in the mesangial area
of patients with IgAN [98, 99] and patients with Henoch-
Scho¨nlein purpura [100]. Therefore, activation of comple-
ment in the renal mesangium by IgA may be mediated
by both the alternative and lectin pathway. Activation
of both pathways is most prominent for pIgA [95, 96,
101]. Therefore, deposited pIgA most likely contributes
to the development of renal damage by complement and
mesangial cell activation. This mesangial damage may
be enhanced by underglycosylation of mesangial IgA.
GalNAc and Gal-exposing glycoforms isolated from pa-
tients with IgAN showed more alternative complement
pathway activation than controls [102]. Furthermore, it
was found that abnormally glycosylated IgA was able to
modulate human mesangial cell functions like integrin ex-
pression and vascular endothelial growth factor (VEGF)
synthesis [103]. Whether the binding of IgA molecules
and components of the lectin pathway like MBL, MASP,
and ficolin are influenced by alterations in glycosylation
of IgA still has to be elucidated.
CONCLUSION
The precise origin and nature of mesangial IgA de-
posits in IgAN remain uncertain. The mesangial IgA
deposits contain at least in part macromolecular IgA
and may be derived from circulating immune complexes.
Searching for responsible antigens for these immune
complexes has not resulted in the identification of a con-
sistent antigen. The basic abnormality in IgAN lies most
probably within the IgA immune system rather than in
the kidney. A deficient primary mucosal immune sys-
tem may result in an exaggerated systemic IgA response,
which results in elevated levels of serum IgA, which is
predominantly IgA1 and polymeric of nature. Since in-
creased IgA production alone is not sufficient to develop
IgAN, physicochemical properties of circulating IgA are
likely to play a role. This is supported by the presence
of altered glycosylation of serum and mesangial IgA in
patients with IgAN. Undergalactosylated IgA containing
complexes bind better to mesangial cells as compared
with circulating complexes of healthy controls. Comple-
ment activation by (polymeric) IgA via the alternative
and lectin pathway may contribute to renal damage.
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